公开(公告)号：US20170119774A1

公开(公告)日：2017-05-04

申请号：US15372269

申请日：2016-12-07

Applicant: G1 Therapeutics, Inc.

Inventor： Jay Copeland Strum ,  John Emerson Bisi ,  Patrick Joseph Roberts ,  Francis Xavier Tavares

IPC: A61K31/527 ,  A61N5/10 ,  A61K38/18 ,  A61K45/06 ,  A61K38/19

CPC classification number: A61K31/527 ,  A61K31/202 ,  A61K31/519 ,  A61K31/702 ,  A61K38/18 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K38/208 ,  A61K45/06 ,  A61N5/10 ,  A61N2005/1094 ,  C07D487/20 ,  A61K2300/00

Abstract: This invention is in the area of improved compounds and methods for transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC), from the damage associated with ionizing radiation (IR) exposure using selective radioprotectants.

公开(公告)号：US20160199350A1

公开(公告)日：2016-07-14

申请号：US14954115

申请日：2015-11-30

Applicant: Peter Wisdom Atadja ,  Ricky Wayne Johnstone ,  Henry Miles Prince ,  Mark John Bishton ,  Simon James Harrison

Inventor： Peter Wisdom Atadja ,  Ricky Wayne Johnstone ,  Henry Miles Prince ,  Mark John Bishton ,  Simon James Harrison

IPC: A61K31/4045 ,  A61K38/22 ,  A61K31/573 ,  A61K31/4152 ,  A61K38/05

CPC classification number: A61K39/395 ,  A61K31/385 ,  A61K31/395 ,  A61K31/404 ,  A61K31/4045 ,  A61K31/4152 ,  A61K31/4965 ,  A61K31/57 ,  A61K31/573 ,  A61K31/69 ,  A61K31/706 ,  A61K38/05 ,  A61K38/12 ,  A61K38/15 ,  A61K38/196 ,  A61K38/22 ,  A61K45/00 ,  A61K45/06 ,  A61K2300/00

Abstract: The invention relates to a combination which comprises: (a) a HDAC inhibitor; and (b) an anti-thrombocytopenia drug, for simultaneous, concurrent, separate or sequential use, especially for use in the treatment of a proliferative diseases. The invention also relates to pharmaceutical compositions or products comprising such a combination, or a method using such a combination

公开(公告)号：US20150174167A1

公开(公告)日：2015-06-25

申请号：US14642254

申请日：2015-03-09

Applicant: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY

Inventor： Janice Marie Brown

IPC: A61K35/15

CPC classification number: A61K35/15 ,  A61K35/19 ,  A61K38/1816 ,  A61K38/193 ,  A61K38/196 ,  A61K2300/00

Abstract: Myeloid function is enhanced by transplantation or infusion of allogeneic myeloid progenitor cells, including CMP, GMP, MEP and MKP cell subsets. Myeloid progenitors ameliorate sequelae of anemia and thrombocytopenia, and can prevent or treat gastrointestinal mucositis associated with chemotherapy, radiotherapy, and the like. The transplantation or infusion may be performed in the absence of HLA typing, and the cells may be mismatched at one or more Class I HLA loci. The transplantation may provide for treatment of ongoing disease, or prevention of disease in high risk patients.

Abstract translation: 通过移植或输注同种异体骨髓祖细胞（包括CMP，GMP，MEP和MKP细胞亚群）增强骨髓功能。 骨髓祖细胞改善贫血和血小板减少症的后遗症，并可预防或治疗与化疗，放疗等相关的胃肠道粘膜炎。 可以在不存在HLA分型的情况下进行移植或输注，并且细胞可能在一个或多个I类HLA基因座处不匹配。 该移植可以提供治疗正在进行的疾病或预防高危患者的疾病。

公开(公告)号：US20140047572A1

公开(公告)日：2014-02-13

申请号：US13838111

申请日：2013-03-15

Applicant: Yuhchyau CHEN ,  J.H. David WU ,  Jane L. LIESVELD ,  Lin GAN

Inventor： Yuhchyau CHEN ,  J.H. David WU ,  Jane L. LIESVELD ,  Lin GAN

IPC: A61K31/4152 ,  G01N33/50 ,  A61K45/06

CPC classification number: A61K31/4152 ,  A01K2207/15 ,  A01K2217/072 ,  A01K2227/105 ,  A01K2267/03 ,  A61K38/196 ,  A61K39/3955 ,  A61K45/06 ,  C07K14/715 ,  C07K16/2866 ,  G01N33/5008 ,  G01N33/5094 ,  G01N2333/524

Abstract: Disclosed are transgenic non-human mammals, which useful for the screening of thrombopoietin mimetics, thrombopoietin receptor agonists, or thrombopoietin receptor antagonists active on the human thrombopoietin receptor. The transgenic non-human mammal has a genome that comprises a stably integrated transgene construct comprising a polynucleotide sequence encoding a humanized thrombopoietin receptor wherein said transgenic non-human mammal has a baseline blood platelet count corresponding to a physiological blood platelet count of a matched non-transgenic non-human mammal. The chimeric thrombopoietin receptor comprises either the transmembrane domain of a human thrombopoietin receptor or both the extracellular and transmembrane domains of a human thrombopoietin receptor operably coupled to a cytoplasmic domain of a non-human thrombopoietin receptor.

公开(公告)号：US08535676B2

公开(公告)日：2013-09-17

申请号：US13476157

申请日：2012-05-21

Applicant: David M. Goldenberg ,  Hans J. Hansen

Inventor： David M. Goldenberg ,  Hans J. Hansen

IPC: A61K39/385

CPC classification number: A61K39/39558 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/655 ,  A61K31/675 ,  A61K31/704 ,  A61K38/164 ,  A61K38/168 ,  A61K38/1816 ,  A61K38/191 ,  A61K38/193 ,  A61K38/196 ,  A61K38/20 ,  A61K38/217 ,  A61K51/1045 ,  A61K51/1048 ,  A61K51/1096 ,  A61K2039/505 ,  C07K16/3007 ,  C07K2317/24 ,  A61K2300/00

Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.

Abstract translation: 本发明提供了包含裸体人源化，嵌合和人抗CEA抗体和治疗剂的组合物，其可用于治疗表达CEA的癌症和其它疾病，以及使用该组合物的治疗方法。

公开(公告)号：US08518883B2

公开(公告)日：2013-08-27

申请号：US12971678

申请日：2010-12-17

Applicant: John E. Baker ,  Yang Shi

Inventor： John E. Baker ,  Yang Shi

IPC: A61P9/10 ,  C07K14/475 ,  C07K14/52 ,  C07K14/715

CPC classification number: A61K38/196

Abstract: A therapeutic or prophylactic treatment method of ischemia, such as due to myocardial infarction, by administering thrombopoietin, alone or in combination with other drugs, to a patient suffering from or at risk of cardiac injury, such as myocardial ischemia. The thrombopoietin is administered in a concentration such that the subject's platelet count or production of platelets is not significantly affected.

Abstract translation: 通过将血小板生成素单独或与其它药物组合施用于患有或有心脏损伤风险的患者（例如心肌缺血）的局部缺血的治疗或预防治疗方法，例如由于心肌梗塞。 血小板生成素的给药浓度使得受试者的血小板计数或血小板的产生不受显着影响。

公开(公告)号：US20130045192A1

公开(公告)日：2013-02-21

申请号：US13508909

申请日：2010-11-09

Applicant: Mayur Movalia ,  Andrea Illingworth ,  Susan Faas McKnight ,  Russell P. Rother

Inventor： Mayur Movalia ,  Andrea Illingworth ,  Susan Faas McKnight ,  Russell P. Rother

IPC: G01N33/566 ,  A61P7/00 ,  A61K31/727 ,  A61P7/02 ,  A61K35/14 ,  A61K38/49

CPC classification number: G01N33/5094 ,  A61K31/352 ,  A61K31/56 ,  A61K31/727 ,  A61K35/19 ,  A61K38/196 ,  A61K38/4886 ,  C07K16/40 ,  G01N33/56972 ,  G01N33/6893 ,  G01N2800/226

Abstract: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.

Abstract translation: 本公开涉及用于检测生物样品中PNH II型细胞群的方法，以及用于基于患者血液中PNH II型细胞的百分比来确定患者是否处于发生血小板减少症或血栓形成的风险增加的方法。 本公开还涉及用于该方法的试剂和共轭物。

公开(公告)号：US08067367B2

公开(公告)日：2011-11-29

申请号：US10667096

申请日：2003-09-18

Applicant: Brian R. MacDonald ,  Kenneth Kaushansky

Inventor： Brian R. MacDonald ,  Kenneth Kaushansky

IPC: A61K38/02 ,  C12N5/00

CPC classification number: A61K38/196 ,  A61K35/28 ,  A61K2300/00

Abstract: A method of increasing hematopoietic stem cell production is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier are also disclosed.

Abstract translation: 公开了增加造血干细胞生产的方法。 该方法包括向受试者施用TPO模拟化合物。 还公开了包含TPO模拟化合物和药学上可接受的载体的药物组合物。

公开(公告)号：US20110288019A1

公开(公告)日：2011-11-24

申请号：US13164707

申请日：2011-06-20

Applicant: Brian R. MacDonald ,  Kenneth Kaushansky

Inventor： Brian R. MacDonald ,  Kenneth Kaushansky

IPC: A61K38/18

CPC classification number: A61K38/196 ,  A61K35/28 ,  A61K2300/00

Abstract: A method of increasing hematopoietic stem cell production is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier are also disclosed.

Abstract translation: 公开了增加造血干细胞生产的方法。 该方法包括向受试者施用TPO模拟化合物。 还公开了包含TPO模拟化合物和药学上可接受的载体的药物组合物。

公开(公告)号：US07919090B2

公开(公告)日：2011-04-05

申请号：US12639298

申请日：2009-12-16

Applicant: David M. Goldenberg ,  Hans J. Hansen

Inventor： David M. Goldenberg ,  Hans J. Hansen

IPC: A61K39/395

CPC classification number: A61K39/39558 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/4745 ,  A61K31/475 ,  A61K31/513 ,  A61K31/519 ,  A61K31/555 ,  A61K31/655 ,  A61K31/675 ,  A61K31/704 ,  A61K38/164 ,  A61K38/168 ,  A61K38/1816 ,  A61K38/191 ,  A61K38/193 ,  A61K38/196 ,  A61K38/20 ,  A61K38/217 ,  A61K51/1045 ,  A61K51/1048 ,  A61K51/1096 ,  A61K2039/505 ,  C07K16/3007 ,  C07K2317/24 ,  A61K2300/00

Abstract: The present invention provides a composition comprising naked humanized, chimeric, and human anti-CEA antibodies and a therapeutic agent, which is useful for treatment of CEA expressing cancers and other diseases, and methods of use in treatment using this composition.